BRPI0619605B8 - composições compreendendo moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, usos das mesmas, método de preparação de uma molécula de anticorpo, e kit - Google Patents
composições compreendendo moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, usos das mesmas, método de preparação de uma molécula de anticorpo, e kitInfo
- Publication number
- BRPI0619605B8 BRPI0619605B8 BRPI0619605A BRPI0619605A BRPI0619605B8 BR PI0619605 B8 BRPI0619605 B8 BR PI0619605B8 BR PI0619605 A BRPI0619605 A BR PI0619605A BR PI0619605 A BRPI0619605 A BR PI0619605A BR PI0619605 B8 BRPI0619605 B8 BR PI0619605B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- variable region
- glycosylated
- antibody molecule
- beta4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05027090.9 | 2005-12-12 | ||
| EP05027090 | 2005-12-12 | ||
| PCT/EP2006/011914 WO2007068429A1 (en) | 2005-12-12 | 2006-12-11 | Antibodies against amyloid beta 4 with glycosylated in the variable region |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0619605A2 BRPI0619605A2 (pt) | 2011-10-11 |
| BRPI0619605A8 BRPI0619605A8 (pt) | 2019-01-15 |
| BRPI0619605B1 BRPI0619605B1 (pt) | 2019-08-13 |
| BRPI0619605B8 true BRPI0619605B8 (pt) | 2021-05-25 |
Family
ID=37745986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0619605A BRPI0619605B8 (pt) | 2005-12-12 | 2006-12-11 | composições compreendendo moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, usos das mesmas, método de preparação de uma molécula de anticorpo, e kit |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US8906370B2 (https=) |
| EP (2) | EP1960428B1 (https=) |
| JP (1) | JP5145241B2 (https=) |
| KR (2) | KR20080077132A (https=) |
| CN (2) | CN102659943B (https=) |
| AR (1) | AR057233A1 (https=) |
| AT (1) | ATE517923T1 (https=) |
| AU (1) | AU2006326301B2 (https=) |
| BR (1) | BRPI0619605B8 (https=) |
| CA (1) | CA2632828C (https=) |
| CR (1) | CR10000A (https=) |
| CY (1) | CY1114783T1 (https=) |
| DK (1) | DK1960428T3 (https=) |
| DO (1) | DOP2006000278A (https=) |
| EC (1) | ECSP088524A (https=) |
| ES (1) | ES2368591T3 (https=) |
| IL (1) | IL191004A (https=) |
| JO (1) | JO2824B1 (https=) |
| MA (1) | MA30038B1 (https=) |
| MY (1) | MY155286A (https=) |
| NO (1) | NO346105B1 (https=) |
| NZ (1) | NZ568241A (https=) |
| PE (3) | PE20100684A1 (https=) |
| PL (1) | PL1960428T3 (https=) |
| PT (1) | PT1960428E (https=) |
| RS (1) | RS52004B (https=) |
| RU (1) | RU2438706C2 (https=) |
| SI (1) | SI1960428T1 (https=) |
| TW (1) | TWI382990B (https=) |
| UA (1) | UA99097C2 (https=) |
| UY (1) | UY30003A1 (https=) |
| WO (1) | WO2007068429A1 (https=) |
| ZA (1) | ZA200805038B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR038568A1 (es) * | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| RU2432362C2 (ru) | 2005-11-30 | 2011-10-27 | Эбботт Лэборетриз | Моноклональные антитела и их применения |
| PL2289909T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał |
| UA99097C2 (ru) * | 2005-12-12 | 2012-07-25 | Ф. Хоффманн-Ля Рош Аг | Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| JP2010512356A (ja) * | 2006-12-11 | 2010-04-22 | エフ．ホフマン−ラ ロシュ アーゲー | 非経口ａベータ抗体製剤 |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| LT2167540T (lt) * | 2007-06-29 | 2018-04-25 | F. Hoffmann-La Roche Ag | Sunkioji grandinė mutantė, pagerinanti imunoglobulino gamybą |
| ES2473623T3 (es) * | 2007-08-20 | 2014-07-07 | Glaxo Group Limited | Procedimiento de producción |
| RS53174B (sr) | 2007-10-05 | 2014-06-30 | Genentech Inc. | Upotreba antiamiloidnog beta antitela u slučaju oboljenja oka |
| KR101247418B1 (ko) * | 2007-12-21 | 2013-03-25 | 에프. 호프만-라 로슈 아게 | 항체 제형 |
| US8163551B2 (en) * | 2008-05-02 | 2012-04-24 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
| US20140213465A1 (en) * | 2011-12-02 | 2014-07-31 | Plaxgen, Inc. | Plaque array methods and compositions for forming and detecting plaques |
| US20120282654A1 (en) * | 2009-04-29 | 2012-11-08 | Schering Corporation | Antibody purification |
| WO2011090720A2 (en) * | 2009-12-29 | 2011-07-28 | Dr. Reddy's Laboratories Ltd | Purification of proteins |
| UY33253A (es) | 2010-03-03 | 2011-09-30 | Boehringer Ingelheim Int | Polipéptidos de unión a a-beta |
| ES2684475T3 (es) | 2010-04-15 | 2018-10-03 | Abbvie Inc. | Proteínas que se unen a beta amiloide |
| RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
| CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
| WO2012142301A2 (en) | 2011-04-12 | 2012-10-18 | Quanterix Corporation | Methods of determining a treatment protocol for and/or a prognosis of a patients recovery from a brain injury |
| SG10201604104PA (en) * | 2011-10-25 | 2016-07-28 | Prothena Therapeutics Ltd | Antibody formulations and methods |
| ES2564281T3 (es) * | 2012-03-08 | 2016-03-21 | F. Hoffmann-La Roche Ag | Formulación de anticuerpos Abeta |
| RU2711552C2 (ru) * | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| CN102998454A (zh) * | 2012-12-11 | 2013-03-27 | 华中师范大学 | 一种检测生物体内邻苯二甲酸二丁酯相对含量的方法 |
| ES2862950T3 (es) * | 2012-12-18 | 2021-10-08 | Univ Rockefeller | Anticuerpos anti-CD4 modificados con glicanos para la prevención y terapia del VIH |
| US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
| EP3594231A1 (en) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Highly galactosylated anti-tnf-alpha antibodies and uses thereof |
| JP6169885B2 (ja) | 2013-05-07 | 2017-07-26 | 株式会社日立製作所 | 精製装置及び精製方法 |
| EP4331605A3 (en) | 2013-09-13 | 2024-05-22 | F. Hoffmann-La Roche AG | Methods and compositions comprising purified recombinant polypeptides |
| ES2915378T3 (es) | 2013-09-13 | 2022-06-22 | Hoffmann La Roche | Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares |
| CN105899192B (zh) | 2013-11-22 | 2019-08-13 | 国立大学法人东京大学 | 药物递送用载体、偶联物及含有这些成分的组合物以及它们的施予方法 |
| JP6744856B2 (ja) | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| WO2015165961A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| MX391086B (es) | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| IL257146B2 (en) | 2015-08-21 | 2025-01-01 | Hoffmann La Roche | Method for reducing host cell proteins by affinity chromatography |
| NZ741067A (en) | 2015-10-02 | 2023-07-28 | Hoffmann La Roche | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| ES2903156T3 (es) * | 2015-10-16 | 2022-03-31 | Hoffmann La Roche | Un procedimiento para hacer funcionar un sistema y un sistema |
| US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| CA3004494A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columiba | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
| US10759837B2 (en) | 2015-11-09 | 2020-09-01 | The University Of British Columbia | Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide |
| US10792477B2 (en) * | 2016-02-08 | 2020-10-06 | Orbusneich Medical Pte. Ltd. | Drug eluting balloon |
| EP3427183A1 (en) * | 2016-03-10 | 2019-01-16 | Genomic Vision | Method of curvilinear signal detection and analysis and associated platform |
| EP3448874A4 (en) * | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| TWI798751B (zh) | 2016-07-01 | 2023-04-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| CN109476729A (zh) | 2016-07-18 | 2019-03-15 | 英属哥伦比亚大学 | 淀粉样蛋白β的抗体 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| EP3632421B1 (en) * | 2017-05-30 | 2025-08-13 | Morinaga Milk Industry Co., Ltd. | Acetic acid and/or an acetic acid salt for use in the treatment of alzheimer-type dementia |
| US12286469B2 (en) | 2017-07-18 | 2025-04-29 | The University Of British Columbia | Humanized antibodies binding to amyloid-beta (A-beta) |
| ES2984844T3 (es) | 2017-07-18 | 2024-10-31 | Univ British Columbia | Anticuerpos contra beta amiloide |
| CN108048477A (zh) * | 2017-12-15 | 2018-05-18 | 南京理工大学 | 基于大肠杆菌表达系统的制备多肽的方法 |
| EP3778875A1 (en) | 2019-08-14 | 2021-02-17 | MaxiVax SA | Immortalized myoblast cell lines and uses thereof |
| MX2023000949A (es) | 2020-07-23 | 2023-02-22 | Othair Prothena Ltd | Anticuerpos anti-beta-amiloide (abeta). |
| PE20231556A1 (es) * | 2020-11-16 | 2023-10-03 | Hoffmann La Roche | Glucoformas de fab ricas en manosa |
| TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
| WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
| CN114720543B (zh) * | 2022-04-06 | 2026-02-24 | 苏州大学 | 一种基于固相糖蛋白t抗原糖肽富集和酶切分析的方法 |
| CN114591429B (zh) * | 2022-05-07 | 2022-08-09 | 北京第一生物化学药业有限公司 | 结合β-淀粉样蛋白的抗体及其用途 |
| TW202434629A (zh) | 2023-01-26 | 2024-09-01 | 愛爾蘭商歐薩爾普羅席納有限公司 | 以抗類澱粉β (ABETA)抗體治療神經病症之方法 |
| KR20260051039A (ko) | 2023-08-09 | 2026-04-15 | 에프. 호프만-라 로슈 아게 | 항-a-베타 단백질 항체, 이의 제조 방법 및 용도 |
| AU2024323186A1 (en) | 2023-08-09 | 2026-01-15 | F. Hoffmann-La Roche Ag | Mono and multispecific anti-trem2 antibodies, methods and uses thereof |
| CN117783359B (zh) * | 2023-12-28 | 2024-12-31 | 中国计量科学研究院 | 一种基于串联质谱的转基因蛋白多靶同检方法 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666829A (en) | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| CA1339014C (en) | 1987-10-08 | 1997-03-25 | Ronald E. Majocha | Antibodies to a4 amyloid peptide |
| JP2780507B2 (ja) | 1991-03-29 | 1998-07-30 | 松下電器産業株式会社 | 内燃機関用フィルタ再生装置 |
| US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| EP0683234B2 (en) | 1993-01-25 | 2007-06-06 | Takeda Chemical Industries, Ltd. | Antibody against beta-amyloid or their derivative and use thereof |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| GB9416007D0 (en) * | 1994-08-08 | 1994-09-28 | Erba Carlo Spa | Anthracyclinone derivatives |
| US5688651A (en) | 1994-12-16 | 1997-11-18 | Ramot University Authority For Applied Research And Development Ltd. | Prevention of protein aggregation |
| CA2222522A1 (en) * | 1995-06-06 | 1996-12-12 | Stemcell Therapeutics L.L.C. | Glycoprotein gp105 on bl3 hematopoietic stem cells |
| AU725609C (en) | 1995-08-18 | 2002-01-03 | Morphosys Ag | Protein/(poly)peptide libraries |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| EP1161449B1 (en) * | 1999-03-04 | 2007-07-04 | Praecis Pharmaceuticals Incorporated | Modulators of beta-amyloid peptide aggregation comprising d-amino acids |
| WO2000077178A1 (en) | 1999-06-16 | 2000-12-21 | Boston Biomedical Research Institute | IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO |
| AU6722300A (en) | 1999-08-31 | 2001-03-26 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders |
| US20020094335A1 (en) | 1999-11-29 | 2002-07-18 | Robert Chalifour | Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases |
| NZ540564A (en) | 1999-11-29 | 2007-04-27 | Neurochem Int Ltd | Vaccine for the prevention and treatment of Alzheimer's and amyloid related diseases |
| EP1125905A1 (en) | 2000-02-16 | 2001-08-22 | Pepscan Systems B.V. | Segment synthesis |
| BRPI0108676B8 (pt) | 2000-02-24 | 2021-05-25 | Lilly Co Eli | anticorpos humanizados que sequestram peptídeo amilóide beta e seus usos no tratamento de condições caracterizadas por formação de placas amiloides, bem como composição farmacêutica que compreende os referidos anticorpos |
| CA2313828A1 (en) | 2000-08-01 | 2002-02-01 | Institut De Recherches Cliniques De Montreal/Ircm | Post-translational processing of .beta.-secretase (bace): the pro-and transmembrane/cytosolic domains affect its cellular activity and amyloid a.beta. production |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| JP2005501220A (ja) | 2000-12-19 | 2005-01-13 | パラチン テクノロジーズ インク． | ペプチドおよび蛋白質の標的特異的折りたたみ部位の識別 |
| ES2437875T3 (es) | 2001-04-30 | 2014-01-14 | Eli Lilly And Company | Anticuerpos humanizados que reconocen el péptido beta-amiloide |
| US7320790B2 (en) | 2001-04-30 | 2008-01-22 | Eli Lilly And Company | Humanized antibodies |
| JP2005503789A (ja) * | 2001-08-17 | 2005-02-10 | イーライ・リリー・アンド・カンパニー | 抗Ａβ抗体 |
| PT1944040E (pt) * | 2001-08-17 | 2012-10-31 | Univ Washington | Método de avaliação para a doença de alzheimer |
| AR038568A1 (es) | 2002-02-20 | 2005-01-19 | Hoffmann La Roche | Anticuerpos anti-a beta y su uso |
| MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
| MXPA05003621A (es) | 2002-10-09 | 2005-10-19 | Rinat Neuroscience Corp | Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos. |
| DE10303974A1 (de) * | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| UA99097C2 (ru) * | 2005-12-12 | 2012-07-25 | Ф. Хоффманн-Ля Рош Аг | Композиция, содержащая антитела к амилоиду бета 4, имеющие гликозилированный вариабельный участок |
| JP2010512356A (ja) * | 2006-12-11 | 2010-04-22 | エフ．ホフマン−ラ ロシュ アーゲー | 非経口ａベータ抗体製剤 |
-
2006
- 2006-12-11 UA UAA200808791A patent/UA99097C2/ru unknown
- 2006-12-11 UY UY30003A patent/UY30003A1/es unknown
- 2006-12-11 NO NO20082874A patent/NO346105B1/no unknown
- 2006-12-11 PE PE2010000354A patent/PE20100684A1/es not_active Application Discontinuation
- 2006-12-11 PE PE2006001587A patent/PE20071002A1/es not_active Application Discontinuation
- 2006-12-11 WO PCT/EP2006/011914 patent/WO2007068429A1/en not_active Ceased
- 2006-12-11 PL PL06829502T patent/PL1960428T3/pl unknown
- 2006-12-11 RS RS20110401A patent/RS52004B/sr unknown
- 2006-12-11 DO DO2006000278A patent/DOP2006000278A/es unknown
- 2006-12-11 PT PT06829502T patent/PT1960428E/pt unknown
- 2006-12-11 US US12/086,309 patent/US8906370B2/en active Active
- 2006-12-11 CA CA2632828A patent/CA2632828C/en active Active
- 2006-12-11 JO JO2006444A patent/JO2824B1/en active
- 2006-12-11 BR BRPI0619605A patent/BRPI0619605B8/pt active IP Right Grant
- 2006-12-11 KR KR1020087012289A patent/KR20080077132A/ko not_active Ceased
- 2006-12-11 KR KR1020127010552A patent/KR101401159B1/ko active Active
- 2006-12-11 CN CN201210137369.8A patent/CN102659943B/zh active Active
- 2006-12-11 SI SI200631096T patent/SI1960428T1/sl unknown
- 2006-12-11 TW TW095146304A patent/TWI382990B/zh active
- 2006-12-11 CN CN2006800463079A patent/CN101351476B/zh active Active
- 2006-12-11 ES ES06829502T patent/ES2368591T3/es active Active
- 2006-12-11 AR ARP060105433A patent/AR057233A1/es unknown
- 2006-12-11 MY MYPI20081349A patent/MY155286A/en unknown
- 2006-12-11 PE PE2010000560A patent/PE20100748A1/es active IP Right Grant
- 2006-12-11 NZ NZ568241A patent/NZ568241A/en unknown
- 2006-12-11 EP EP06829502A patent/EP1960428B1/en active Active
- 2006-12-11 AU AU2006326301A patent/AU2006326301B2/en active Active
- 2006-12-11 DK DK06829502.1T patent/DK1960428T3/da active
- 2006-12-11 AT AT06829502T patent/ATE517923T1/de active
- 2006-12-11 JP JP2008543748A patent/JP5145241B2/ja active Active
- 2006-12-11 EP EP11169488A patent/EP2377886A1/en not_active Withdrawn
- 2006-12-11 RU RU2008128138/10A patent/RU2438706C2/ru active
-
2008
- 2008-04-27 IL IL191004A patent/IL191004A/en active IP Right Grant
- 2008-05-20 CR CR10000A patent/CR10000A/es unknown
- 2008-06-09 MA MA31014A patent/MA30038B1/fr unknown
- 2008-06-10 ZA ZA200805038A patent/ZA200805038B/xx unknown
- 2008-06-10 EC EC2008008524A patent/ECSP088524A/es unknown
-
2011
- 2011-09-16 CY CY20111100899T patent/CY1114783T1/el unknown
-
2014
- 2014-11-07 US US14/536,262 patent/US9272031B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0619605B8 (pt) | composições compreendendo moléculas de anticorpos contra amilóide beta4 com glicosilação na região variável, usos das mesmas, método de preparação de uma molécula de anticorpo, e kit | |
| BRPI0619748B8 (pt) | anticorpo monoclonal, polinucleotídeo, composição, mistura, uso de um anticorpo monoclonal ou uma parte funcional do mesmo, método para preparar uma composição farmacêutica, linhagem celular de hibridoma isolado, método de diagnóstico de uma doença ou condição associada a amilóide em um paciente, método para diagnosticar uma predisposição para uma doença ou condição, método para monitorar doença residual mínima, método para prever a responsividade de um paciente e kits de teste | |
| BR112021012222A8 (pt) | Molécula de ligação direcionada à célula melhorada | |
| BRPI0816784A8 (pt) | Fatores neuro-endócrinos para o tratamento de doenças degenerativas | |
| BRPI0410338A (pt) | composição farmacêutica compreendendo um constructo de anticorpo biespecìfico para epcam, processo para sua produção, uso de um constructo biespecìfico, kit contendo o mesmo e método para a prevenção, tratamento ou alìvio de uma doença tumoral | |
| BRPI0509847B8 (pt) | anticorpo que se liga à p-seletina, seu método de preparo e uso, vetor, composição e kit | |
| BRPI0619357A8 (pt) | Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits | |
| BR0209177A (pt) | Anticorpo especìfico a tumor recombinante e uso do mesmo | |
| UY28170A1 (es) | Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes. | |
| BRPI0408097A (pt) | composição de insulina oral e processos para a produção e para o uso da mesma | |
| NO20083793L (no) | Antistoffer mot amyloid-beta peptid | |
| BRPI0511703B8 (pt) | composto, composição farmacêutica, e, métodos de tratar diabete melito tipo 2, de retardar o início do diabete melito tipo 2, de tratar hiperglicemia, diabete ou resistência à insulina, obesidade, síndrome x, um distúrbio lipídico, aterosclerose, e uma condição | |
| BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
| BR0315720A (pt) | Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário | |
| BRPI0411552A (pt) | anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea | |
| BR112012001984B8 (pt) | anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica | |
| BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
| BRPI0609765A8 (pt) | mistura de isoalcano, método para a preparação da mesma, composição cosmética ou farmacêutica, e, uso de uma mistura de isoalcano | |
| BR0309421A (pt) | Composições de proteìna associada com corpo oleoso e métodos de uso destas para reduzir o risco de doença cardiovascular | |
| BRPI0211635B8 (pt) | composto ciclo-hexil-sulfona, uso do mesmo, e, composição farmacêutica | |
| BR0101492A (pt) | Misturas de pelo menos um enchedor e compostosde organossilìcio, processo para sua preparação eseu uso | |
| BRPI0407031A (pt) | Composições e métodos para tratamento de câncer empregando igsf9 e liv-1 | |
| BR0309896A (pt) | Compostos, uso em um composto, composição farmacêutica, composição cosmética, uso cosmético de uma composição | |
| BRPI0415541A (pt) | molécula inibidora de angiogênese, uso de uma molécula inibidora de angiogênese, composição terapêutica para tratamento de cáncer, composição para diagnóstico destinada ao diagnóstico de cáncer, uso do anticorpo h33, produzido pelo hibridoma 13h33, fragmento de anticorpo h33 conforme produzido pelo hibridoma 13h33, e uso de um fragmento ou derivado do anticorpo h33 | |
| BR112023020801A2 (pt) | Anticorpo ou fragmento de ligação ao antígeno, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação de um anticorpo ou fragmento de ligação ao antígeno, um conjugado anticorpo-fármaco ou uma composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/08/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |